Tumour Lysis Syndrome Associated with Lenvatinib: an Investigator-Initiated, Retrospective Observational Post-Authorisation Safety Study (TELSTAR)

Study identification

• EU PAS number:
  EUPAS1000000977
• Study ID:
  1000000977
• Official title and acronym:
  Tumour Lysis Syndrome Associated with Lenvatinib: an Investigator-Initiated, Retrospective Observational Post-Authorisation Safety Study (TELSTAR)
• DARWIN EU® study:
  No
• Study countries:
  Portugal
• Study description:
  No information provided.
• Study status:
  Planned

Study timelines

Date when funding contract was signed

Planned:15/05/2026

Study start date

Planned:15/05/2026

Date of final study report

Planned:01/03/2027

Sources of funding

No external funding

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable